Semaglutide

Fat LossFDA-Approved

Overview

Semaglutide is a GLP-1 receptor agonist FDA-approved under brand names Ozempic® (T2D), Wegovy® (weight management), and Rybelsus® (oral T2D). It represents a major advance in metabolic medicine with demonstrated efficacy for glycemic control, weight management, and cardiovascular risk reduction.

Evidence Strength

🟢

Human Clinical Evidence

Supported by peer-reviewed human clinical trials

🟢Human Clinical Evidence

🟡Limited Human Evidence

🟠Mostly Animal Research

🔴Preclinical / Laboratory

This information is for educational and research purposes only. It does not constitute medical advice. Always consult a qualified healthcare professional before making any health decisions.